News

The Lancet2d
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study ...
This study is registered with ClinicalTrials.gov, NCT04655755, and is currently enrolling participants. Findings. Between Jan 21, 2021, and Jan 20, 2023, we enrolled 39 patients (nine in phase 1 and ...
UroToday5d
ASCO GU 2022: Phase 1/2 Study of ARV-110, an Androgen Receptor PROTAC Degrader, in Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2022 results of a phase 1/2 study examining the role of ARV-110 in metastatic castration-resistant prostate cancer (mCRPC), novel AR protein degrade ARV-110 demonstrates clinical activity in a ...